NSETrading Window26 Jun 2026 · 26 Jun 2026, 04:33 pm
Trading Window
Jagsonpal Pharmaceuticals Limited · JAGSNPHARM
✦ AI Summarytrading_window
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in securities of Jagsonpal Pharmaceuticals Limited will remain closed for Designated Persons and their immediate relative(s) from July 01, 2026, and will open 48 hours after the declaration of unaudited financial results for the quarter ended on June 30, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk3/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Attachments (1)
📄pdf
Download →
JAGSNPHARM_26062026163232_TradingWindow_Signed.pdf
View document text
Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,
Sector-18, Gurugram -122015, Haryana (India)
Ph.: +91 124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com
CIN. : L74899DL1978PLC009181
June 26, 2026
The Department of Corporate Services- Listing The Department of Corporate Services- Listing
BSE Ltd, National Stock Exchange of India Ltd
Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G,
Dalal Street Bandra Kurla Complex,
Mumbai-400 001 Bandra (E) Mumbai – 400 051
Scrip Code: 507789 Symbol: JAGSNPHARM
Subject: Intimation of Closure of Trading Window
In terms of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Conduct to regulate,
monitor and report trading by designated persons & immediate relatives of Designated Persons, the Trading
Window for dealing in securities of Jagsonpal Pharmaceuticals Limited ("the Company") would remain closed
for Designated Persons and their immediate relative(s) with effect from Wednesday, July 01, 2026 and will open
48 (Forty Eight) hours after declaration of unaudited financial results for the quarter ended on June 30, 2026.
The date of Board Meeting for declaration of unaudited financial results of the Company for the quarter ended
on June 30, 2026 will be intimated in due course.
We request you to take the above on record.
Thanking you,
Yours faithfully,
For Jagsonpal Pharmaceuticals Limited
Pratham Rawal
Company Secretary & Compliance Officer
Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India)
Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070